Ovarian carcinosarcoma

Summary

Ovarian carcinosarcoma (MONDO:0003792) is a disease and 26 clinical trials. Top therapeutic interventions include diphtheria toxoid, eribulin mesylate, and ifosfamide. A subtype of carcinosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 26

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.12	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian carcinosarcoma
Mondo ID	MONDO:0003792
EFO	EFO:1000412
Orphanet	213512
DOID	DOID:6170
NCIT	C9192
SNOMED CT	702368000
UMLS	C0392998
MedGen	140705
GARD	0007296
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: carcinosarcoma of ovary · carcinosarcoma of the ovary · malignant mixed mesodermal Mullerian neoplasm of ovary · malignant mixed mesodermal Mullerian neoplasm of the ovary · malignant mixed mesodermal Mullerian tumor of ovary · malignant mixed mesodermal Mullerian tumor of the ovary · malignant mixed mesodermal Mullerian tumour of ovary · malignant mixed mesodermal Mullerian tumour of the ovary · malignant mixed mesodermal Müllerian neoplasm of ovary · malignant mixed mesodermal Müllerian neoplasm of the ovary · malignant mixed mesodermal Müllerian tumor of ovary · malignant mixed mesodermal Müllerian tumor of the ovary · malignant mixed mesodermal Müllerian tumour of ovary · malignant mixed mesodermal Müllerian tumour of the ovary · malignant mixed Müllerian tumour of the ovary · MMMT of the ovary · ovarian carcinosarcoma · ovarian carcinosarcoma/malignant mixed mesodermal tumor · ovarian carcinosarcoma/malignant mixed mesodermal tumour · ovarian malignant mesodermal (Mullerian) mixed tumor (+25 more)

Data availability: 19 cell lines.

Disease family

This is a subtype of carcinosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › carcinosarcoma › ovarian carcinosarcoma

Related subtypes (2): fallopian tube carcinosarcoma, uterine carcinosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 26.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	12
PHASE1	7
PHASE1/PHASE2	3
Not specified	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03651206	PHASE2/PHASE3	RECRUITING	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
NCT00954174	PHASE3	UNKNOWN	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
NCT02101775	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03449108	PHASE2	ACTIVE_NOT_RECRUITING	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT04919629	PHASE2	RECRUITING	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT05619913	PHASE2	RECRUITING	EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
NCT05902988	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05920798	PHASE1/PHASE2	RECRUITING	Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT06639074	PHASE2	RECRUITING	Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT00390234	PHASE2	COMPLETED	Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
NCT00511992	PHASE2	COMPLETED	Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
NCT01010126	PHASE2	COMPLETED	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
NCT02364713	PHASE2	TERMINATED	MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT03610490	PHASE2	TERMINATED	Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
NCT03648489	PHASE2	COMPLETED	Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
NCT04149275	PHASE2	WITHDRAWN	Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
NCT06393751	PHASE1/PHASE2	WITHDRAWN	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
NCT04092270	PHASE1	ACTIVE_NOT_RECRUITING	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT06483048	PHASE1	RECRUITING	MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT00085358	PHASE1	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00352300	PHASE1	COMPLETED	Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
NCT00989651	PHASE1	COMPLETED	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT03924245	PHASE1	TERMINATED	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT03641287	Not specified	TERMINATED	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DIPHTHERIA TOXOID	4	1
ERIBULIN MESYLATE	4	1
IFOSFAMIDE	4	1
LIFILEUCEL	4	1
NIRAPARIB	4	1
PEGCETACOPLAN	4	1
TEMSIROLIMUS	4	1
TETANUS TOXOID	4	1
TOPOTECAN HYDROCHLORIDE	4	1
VELIPARIB	3	2
ENTINOSTAT	3	1
ADAVOSERTIB	2	1
ASTX-660	1	1
NEDISERTIB	1	1
CHEMBL4215501	0	1
CHEMBL4849721	0	1
EXELIXIS	0	1